Product Images Rizatriptan Benzoate

This is a graph showing the estimated probability of response to a placebo and Rizatriptan Benzoate Tablets of 5mg and 10mg doses over time, with hours post-dose on the x-axis and probability on the y-axis.*

The text describes the process of separating one blister unit from a blister pack by tearing along the dotted lines until it is fully separated. This could be a set of instructions for a medication or other product contained in a blister pack.*

This is a medication called Rizatriptan Benzoate 10mg ODT, which comes in a bottle of 6 tablets. Each tablet contains 14.53mg of rizatriptan benzoate, USP equivalent to 10mg rizatriptan. It has a white to off-white, round, uncoated shape, debossed "10" on one side and plain on the other side. The lot number is 00000 and the product ID is RR056306. It needs to be stored at 20°-25°C (68°-77°F) and kept out of the reach of children. This medication was manufactured by Natco Pharma Limited in Kothur-509 228, AP, India and relabeled by Proficient Rx LP in Thousand Oaks, CA 91320.*

This is a plot of the estimated probability of achieving a response to Rizatriptan Benzoate Orally Disintegrating tablets for migraine headache treatment. The plot is based on data obtained from 2 placebo-controlled outpatient trials that show evidence of efficacy. Patients not responding within 2 hours or taking additional treatments are censored at 2 hours.*

This is a figure (Figure 2) that shows the estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in Pooled Studies 1, 2, 3, and 4. The Kaplan-Meier plot is based on data obtained in four placebo-controlled outpatient clinical trials. Patients who did not use additional treatments were censored at 24 hours. The plot includes both patients who had headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.*

Figure 4 shows the estimated probability of patients taking a second dose of Rizatriptan Benzoate orally disintegrating tablets or other medication for migraines over 24 hours following the initial dose of study treatment in Pooled Studies 5 and 6. The Kaplan-Meier plot is based on data obtained in two placebo-controlled outpatient clinical trials. Patients who did not use additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.*